Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?

IF 4.7 2区医学 Q1 ONCOLOGY Current Oncology Reports Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI:10.1007/s11912-024-01501-0

Ilana Schlam, Joshua Dower, Filipa Lynce

{"title":"Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?","authors":"Ilana Schlam, Joshua Dower, Filipa Lynce","doi":"10.1007/s11912-024-01501-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: To summarize the treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive disease and triple-negative breast cancer (TNBC) who have residual disease after preoperative systemic therapy.Recent findings: There has been a shift towards neoadjuvant systemic therapy for selected patients with HER2-positive and TNBC. Assessing the tumor's response to therapy provides prognostic information and allows individualization of the postoperative treatment for these patients based on the tumor response to neoadjuvant therapy. Patients with TNBC with residual disease after neoadjuvant therapy can be treated with pembrolizumab, capecitabine, or olaparib. Those with HER2-positive disease are treated with adjuvant trastuzumab emtansine. The treatment of early breast cancer has evolved significantly, and patient outcomes continue to improve. As better treatments are developed, we will need biomarkers to determine which patients may benefit from certain therapies to continue to improve outcomes by right-sizing treatments and limiting toxicities.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01501-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To summarize the treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive disease and triple-negative breast cancer (TNBC) who have residual disease after preoperative systemic therapy.

Recent findings: There has been a shift towards neoadjuvant systemic therapy for selected patients with HER2-positive and TNBC. Assessing the tumor's response to therapy provides prognostic information and allows individualization of the postoperative treatment for these patients based on the tumor response to neoadjuvant therapy. Patients with TNBC with residual disease after neoadjuvant therapy can be treated with pembrolizumab, capecitabine, or olaparib. Those with HER2-positive disease are treated with adjuvant trastuzumab emtansine. The treatment of early breast cancer has evolved significantly, and patient outcomes continue to improve. As better treatments are developed, we will need biomarkers to determine which patients may benefit from certain therapies to continue to improve outcomes by right-sizing treatments and limiting toxicities.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

应对 HER2 阳性和三阴性乳腺癌的残留疾病：下一步是什么？

综述目的：总结人表皮生长因子受体 2（HER2）阳性和三阴性乳腺癌（TNBC）患者术前系统治疗后残留疾病的治疗策略：最近的研究结果：对于选定的HER2阳性和TNBC患者，新辅助全身治疗已成为一种趋势。评估肿瘤对治疗的反应可提供预后信息，并根据肿瘤对新辅助治疗的反应为这些患者提供个体化的术后治疗。新辅助治疗后有残留病灶的TNBC患者可以接受pembrolizumab、卡培他滨或奥拉帕利的治疗。HER2 阳性患者可接受曲妥珠单抗 emtansine 辅助治疗。早期乳腺癌的治疗已经有了很大的发展，患者的治疗效果也在不断改善。随着更好疗法的开发，我们将需要生物标记物来确定哪些患者可能从某些疗法中获益，从而通过合理调整治疗方案和限制毒性来继续改善疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.